Stocktoria
Seres Therapeutics, Inc. MCRB
Seres Therapeutics, Inc. (MCRB) earns a Piotroski F-score of 5/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $789,000 at a 721.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MCRB | Seres Therapeutics, Inc. | 5/9 | — | 12 | — |
| HYPD | HYPERION DEFI, INC. | 5/9 | -16.62 | — | — |
| ONCO | Onconetix, Inc. | 4/9 | — | — | — |
| BGMS | Bio Green Med Solution, Inc. | 3/9 | — | — | — |
| RLYB | Rallybio Corp | 3/9 | 0.76 | — | — |
| LEXX | Lexaria Bioscience Corp. | 4/9 | — | — | — |
| RFL | Rafael Holdings, Inc. | 3/9 | 0.8 | — | — |
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
FAQ
Is MCRB financially healthy?
Seres Therapeutics, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).
Does MCRB pay a dividend?
No, Seres Therapeutics, Inc. does not currently pay a dividend.
How profitable is MCRB?
In FY2025, Seres Therapeutics, Inc. had a net margin of 721.9% and a return on equity of 12.9%.
What is MCRB's P/E ratio?
Seres Therapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 12.0×, based on its latest annual earnings.
What is the analyst price target for MCRB?
The average Wall-Street price target for Seres Therapeutics, Inc. is $17.00, about 260.2% above the recent price, from 2 analysts (consensus: strong buy).
Is MCRB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Seres Therapeutics, Inc.: a Piotroski F-score of 5/9, a P/E of about 12.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.